Latest evidence on gout management: what the clinician needs to know.
Article Details
- CitationCopy to clipboard
Burns CM, Wortmann RL
Latest evidence on gout management: what the clinician needs to know.
Ther Adv Chronic Dis. 2012 Nov;3(6):271-86. doi: 10.1177/2040622312462056.
- PubMed ID
- 23342241 [ View in PubMed]
- Abstract
Until recently, the last drug approved for the treatment of gout by the United States Food and Drug Administration was allopurinol in 1966. Since 2008, two new drugs for the treatment of gout, febuxostat and pegloticase, have been approved in the US. Febuxostat has been approved in the EU and pegloticase approval is anticipated. A new single-ingredient colchicine preparation is available in the US, and the treatment recommendations for the use of colchicine in acute gout have evolved, now favoring a low-dose regimen. Several other exciting drugs are in development. Herein, we review some of basic principles in the diagnosis and staging of gout. We then examine current treatment principles, with particular attention to febuxostat and pegloticase, offering suggestions as to where they might fit into a modern therapeutic algorithm for gout treatment. We then present available data on several exciting new agents in development, including interleukin-1 inhibitors, and relate them to advances in our understanding of gout pathogenesis. We conclude with some important nonpharmacologic principles for optimal management of this ancient and eminently treatable disease. Dedicated gout research, going on quietly in the background of other breathtaking advances in rheumatology, is now paying off. This comes at a time when the number of patients affected by gout continues to rise, mainly due to an epidemic of obesity. An effort to improve lifestyle choices as a society and better management of the disease by clinicians should have a positive impact on gout incidence and outcome in our lifetimes.
DrugBank Data that Cites this Article
- Pharmaco-metabolomics
Drug Drug Groups Metabolite Change Description Probenecid Approved Investigational Uric acid decreased Probenecid decreases the level of Uric acid in the blood Sulfinpyrazone Approved Uric acid decreased Sulfinpyrazone decreases the level of Uric acid in the blood Benzbromarone Investigational Withdrawn Uric acid decreased Benzbromarone decreases the level of Uric acid in the blood Oxypurinol Investigational uric acid decreased Oxypurinol decreases the level of uric acid in the blood Pegloticase Approved Investigational uric acid decreased Pegloticase decreases the level of uric acid in the blood Pegloticase Approved Investigational allantoin increased Pegloticase increases the level of allantoin in the blood Rasburicase Approved Investigational allantoin increased Rasburicase increases the level of allantoin in the blood